Skip to content

Application of esmketamine hydrochloride in ultrasonic bronchoscopy (EBUS)

Study on anesthetic application of esmketamine in painless ultrasonic bronchoscopy

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2200058825
Enrollment
Unknown
Registered
2022-04-17
Start date
2022-05-01
Completion date
Unknown
Last updated
2024-01-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Respiratory diseases

Interventions

Experimental group:Esmketamine+propofol
Control group:Propofol

Sponsors

The First Affiliated Hospital of Zhengzhou University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Patients to be examined by painless ultrasound bronchoscopy; 2. Age 18-65 years old, regardless of gender; 3. Body mass index (BMI) 18.5-30kg/m2; 4. The American Society of Anesthesiologists (ASA) is classified as grade I ~ III; 5. Voluntarily participate and sign informed consent.

Exclusion criteria

Exclusion criteria: 1. Patients who the investigator considered inappropriate to participate in the trial; 2. Patients with contraindications to sedation/anesthesia or previous history of abnormal recovery of sedation/anesthesia; 3. Those who are known to be allergic to local anesthetics, propofol, benzodiazepines, and opioids; 4. Have a history of serious heart, brain, liver, kidney, and metabolic diseases.

Design outcomes

Primary

MeasureTime frame
Occurrence of intraoperative hypotension;Improved anesthesia recovery time;

Secondary

MeasureTime frame
Vital signs;Time related indicators;Types and doses of drugs used during operation;Satisfaction score;Occurrence of adverse reactions;

Countries

China

Contacts

Public ContactYunqi Lv

The First Affiliated Hospital of Zhengzhou University

lyq260703@163.com+86 13939019005

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026